Interestingly, erbB3 signalling has also been implicated in mediating resistance to IGF-IR-targeted agents in hepatocellular carcinoma cells [39], but whether it plays a similar role in breast cancer remains to be determined. This evidence concerns the gene ERBB3 and breast carcinoma.